Provided by Tiger Fintech (Singapore) Pte. Ltd.

Adaptimmune Therapeutics PLC

0.2450
+0.00281.16%
Pre-market: 0.24500.00000.00%08:27 EDT
Volume:937.87K
Turnover:222.59K
Market Cap:64.94M
PE:-0.84
High:0.2500
Open:0.2378
Low:0.2300
Close:0.2422
Loading ...

Adaptimmune Therapeutics Cut to Neutral From Outperform by Mizuho

Dow Jones
·
26 Jun

Adaptimmune Therapeutics Plc : Mizuho Cuts to Neutral From Outperform; Cuts Target Price to $0.5 From $1.50

THOMSON REUTERS
·
26 Jun

Mizuho Downgrades Adaptimmune Therapeutics to Neutral From Outperform, Cuts Price Target to $0.50 From $1.50 on Solvency Concerns

MT Newswires Live
·
26 Jun

European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading

MT Newswires Live
·
25 Jun

European Equities Traded in the US as American Depositary Receipts Retreat Friday

MT Newswires Live
·
20 Jun

European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading

MT Newswires Live
·
17 Jun

European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

MT Newswires Live
·
16 Jun

European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

MT Newswires Live
·
02 Jun

Adaptimmune Therapeutics plc Conducted Annual General Meeting

Reuters
·
30 May

European Equities Traded in the US as American Depositary Receipts Modestly Higher in Thursday Trading

MT Newswires Live
·
29 May

Context Therapeutics Appoints Dr. Karen Chagin as Chief Medical Officer, Effective June 9, 2025

Reuters
·
29 May

European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading

MT Newswires Live
·
28 May

European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading

MT Newswires Live
·
15 May

European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading

MT Newswires Live
·
14 May

Adaptimmune Therapeutics PLC reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
14 May

Adaptimmune Therapeutics Plc: Continuing to Implement Cost Reduction Measures and Explore Strategic Options

THOMSON REUTERS
·
13 May

Adaptimmune Therapeutics Q1 EPS $(0.03) Beats $(0.12) Estimate, Sales $7.29M Beat $6.17M Estimate

Benzinga
·
13 May

Adaptimmune Therapeutics Q1 Net Income USD -47.6 Million

THOMSON REUTERS
·
13 May

European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

MT Newswires Live
·
12 May

Adaptimmune Therapeutics PLC expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
10 May